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background: Contrast-induced nephropathy (CIN) is a potential 
complication after percutaneous coronary intervention (PCI). 
The pathogenesis is associated to inflammatory mechanisms, 
endothelial dysfunction and oxidative stress and the use of 
statins, due to their pleiotropic effects, has been investi-
gated in this setting. We assessed whether a preload dose 
of rosuvastatin prior to elective PCI in patients on chronic 
statin reduces the incidence of CIN. Methods: Prospective, 
randomized, open label, single-center study. Patients were 
divided according to the use (group 1) or not (group 2) of 
rosuvastatin 40 mg, 2-6 hours prior to PCI. The frequency 
of CIN was compared between the two groups as well as 
in the diabetic and renal dysfunction subgroups. Results: 
We included 135 patients, with 60.7 + 9.3 years of age, 
randomized to group 1 (n = 67) or group 2 (n = 68). The 
prevalence of diabetes was 31.1% and the prevalence of 
creatinine clearance < 60 ml/min was 13.3%. The incidence 
of CIN was 8.1% and there was no difference between groups 
(9% vs. 7.4%; P = 0.89). The incidence of CIN in diabetic 
patients was 15% vs. 13.6% (P = 0.75) and in those with 
renal dysfunction it was 12.5% vs. 0 (P = 0.93). Conclusions: 
The use of a preload dose of rosuvastatin at its maximum 
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RESUMo
Impacto na Função Renal de uma Dose  
de Reforço de Rosuvastatina Prévia a Intervenção 
Coronária Percutânea Eletiva nos Pacientes  
em Uso Crônico de Estatina
Introdução: A nefropatia induzida pelo contraste (NIC) é uma 
complicação potencial após a intervenção coronária percutânea 
(ICP). A patogênese está associada a mecanismos inflamatórios, 
disfunção endotelial e estresse oxidativo, e as estatinas, por 
seus efeitos pleiotrópicos, vêm sendo analisadas nesse cenário. 
Avaliamos se uma dose de reforço de rosuvastatina pré-ICP 
eletiva, em pacientes em uso crônico de estatina, reduz a 
ocorrência de NIC. Métodos: Estudo prospectivo, randomizado, 
aberto, realizado em único centro. Os pacientes foram divididos 
de acordo com a utilização (grupo 1) ou não (grupo 2) de 
40 mg de rosuvastatina, 2 a 6 horas pré-ICP. A frequência de 
NIC foi comparada entre os dois grupos e nos subgrupos de 
diabéticos e com disfunção renal prévia. Resultados: Foram 
incluídos 135 pacientes, com idade de 60,7 ± 9,3 anos, ran-
domizados para o grupo 1 (n = 67) ou para o grupo 2 (n = 
68). A prevalência de diabetes foi de 31,1% e de clearance 
de creatinina < 60 ml/min, de 13,3%. A incidência de NIC 
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dosage did not exert a protective effect in renal function of 
chronic statin users undergoing elective PCI.
 
 
 
 
 
 
DESCRIPtoRS: Angioplasty. Contrast media. Statins. Creatinine. 
Kidney diseases.
C ontrast-induced nephropathy (CIN) is a potential complication of percutaneous coronary intervention (PCI). CIN is the third leading cause of in-hospital 
acute renal failure, occurring in approximately 7% 
of patients exposed to iodinated contrast agents, and 
usually presents spontaneous resolution.1,2 However, CIN 
may be associated with a longer hospital stay, increased 
morbidity and mortality, and higher hospitalisation 
costs, especially in those patients who require renal 
replacement therapy.3
The pathogenesis of CIN is not well understood but 
has been linked to inflammation, endothelial dysfunc-
tion, and oxidative stress.4 Pre-existing kidney disease, 
diabetes mellitus, left ventricular dysfunction, advanced 
age, and the use of large amounts of iodinated contrast 
are all major risk factors for CIN.5,6
Statins are widely used in clinical practice for their 
cholesterol-lowering effects, especially in patients with 
atherosclerotic disease. The effects of statins, however, 
extend beyond cholesterol reduction and include improved 
endothelial function and potential anti-inflammatory 
and anti-oxidative effects.7
Short-term pre-treatment with statins is associated 
with favorable outcomes in various clinical scenarios, 
such as the prevention of peri-PCI myocardial injury 
or atrial fibrillation after cardiac surgery. Recent studies 
have suggested that the pre-PCI administration of statins 
can also prevent the occurrence of CIN.8
The present study sought to evaluate the effects of 
a preload dose of rosuvastatin prior to elective PCI in 
patients receiving chronic statin treatment.
Methods
This prospective, randomized, open, single-center 
study included patients with coronary artery disease who 
were referred for the elective percutaneous implantation 
of at least one stent.
Those patients diagnosed with acute coronary 
syndrome for < 30 days, restenotic lesions, or lesions 
in venous or arterial grafts were excluded.
All patients included in this analysis had been re-
ceiving statin treatment for at least 30 days. After signing 
the informed consent, the patients were divided into 
two groups: those patients who would (group 1) and 
those who would not (group 2) receive a maximal dose 
of rosuvastatin (40 mg) two to six hours before the PCI.
Blood samples were collected from both groups to 
analyse serum creatinine levels before and 24 hours 
after the procedure. Creatinine clearance was also eva-
luated before and after the procedure using the formula 
developed by Cockcroft & Gault. Those with a pre-PCI 
creatinine clearance < 60 mL/min received intravenous 
hydration (0.9% saline, 1 mL/kg/hour in the case of 
normal left ventricular function or 0.5 mL/kg/hour in 
the case of left ventricular dysfunction) for at least six 
hours before and 12 hours after PCI, according to the 
institution’s protocol.
study objectives and definitions
The CIN frequency, variations in creatinine levels 
(pre-and post-Cr) and creatinine clearance rates (pre-
and post-CrCl), and percentage variation in creatinine 
clearence of the two groups were compared. The sub-
groups containing diabetic patients with renal dysfunc-
tion were also evaluated.
CIN was defined as an absolute increase in the 
serum creatinine level to ≥ 0.5 mg/dL or a ≥ 25% 
increase in the creatinine level in 24 hours.5,9
statistical analysis
The categorical data are shown as absolute numbers 
and percentages, and the continuous data are shown as 
the means ± standard deviation. The categorical variables 
were compared using the chi-squared test or Fisher’s 
exact test. The continuous variables were compared 
with the Student’s t-test (paired and non-paired). The 
Mann-Whitney U test was used for the non-parametric 
variables. A two-tailed P-value of < 0.05 was considered 
to be statistically significant. The Statistical Package for 
Social Sciences (SPSS – Chicago, USA), release 13, was 
used for all analyses.
foi de 8,1% e não mostrou diferença entre os grupos (9% 
vs. 7,4%; P = 0,89). A incidência de NIC nos diabéticos foi 
de 15% vs. 13,6% (P = 0,75) e nos portadores de disfunção 
renal prévia foi de 12,5% vs. 0 (P = 0,93). Conclusões: O uso 
de uma dose de reforço de rosuvastatina em sua posologia 
máxima não exerceu efeito protetor renal nos pacientes em 
uso crônico de estatina submetidos a ICP eletiva.
DESCRItoRES: Angioplastia. Meios de contraste. Estatinas. 
Creatinina. Nefropatias.
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tAbLE 1 
Distribution of demographic procedural variables by group
Variables 
Group 1
(n = 67)
Group 2
(n = 68) p
Age, years (mean + SD) 59.4 ± 8.6 62.2 ± 9.8 0.08 
Female, n (%) 29 (43.3) 16 (23.5) 0.01 
Diabetes, n (%) 20 (29.9) 22 (32.4) 0.75 
Smoking, n (%) 14 (20.8) 17 (25) 0.57 
Dyslipidaemia, n (%) 49 (73.1) 53 (77.9) 0.52 
Access route, n (%) 0.67 
Radial 38 (56.7) 41 (60.3) 
Femoral 29 (43.3) 27 (39.7) 
Contrast volume, mL 72.2 78.2 0.35 
Type of contrast, n (%) > 0.99 
High osmolarity 27 (40.3) 27 (39.7) 
Low osmolarity 40 (59.7) 41 (60.3) 
Serum cr, mg/dl
Pre- PCI 0.89 ± 0.24 0.98 ± 0.21 0.02
Pos t- PCI 0.91 ± 0.26* 0.99 ± 0.24† 0.06 
CrCl, mL/min/1.73 m2
Pre 96.1 ± 31.3 87.5 ± 32.2 0.15 
Post 93.4 ± 29.8‡ 86.4 ± 29.7§ 0.06 
*Serum cr pre vs. post = 0.7; †Serum cr pre vs. post = 0.8; ‡crcl pre vs. post = 0.6; §crcl pre vs. post = 0.9.
CrCl = creatinine clearance, Cr = creatinine, SD = standard deviation, PCI = percutaneous coronary
Results
One hundred thirty-five patients undergoing elective 
PCI at the Instituto Dante Pazzanese de Cardiologia 
(Sao Paulo, SP, Brazil) between June of 2010 and May 
of 2011 who met the study inclusion criteria were 
randomized to group 1 (n = 67) or group 2 (n = 68).
The mean age of the patients was 60.7 ± 9.3 years. 
The prevalence of diabetes was 31.1% (n = 42). The 
prevalence of pre-existing renal dysfunction (i.e., those 
patients with creatinine clearance values < 60 mL/min) 
was 13.3% (n = 18). The mean volume of contrast used 
per procedure was 75.5 ± 32.1 mL.
Table 1 shows the demographic and procedural 
variables for both of the groups. With the exception 
of gender, with females being more prevalent in group 
1, no significant differences were observed between 
the two groups.
The incidence of CIN in the entire study population 
was 8.1% and did not differ between the two groups 
(9% in group 1 vs. 7.4% in group 2, P = 0.89).
The variations in serum creatinine levels (pre-PCI vs. 
post-PCI) were negative, indicating increased creatinine 
values after the PCI procedure (group 1, mean of −0.239 
mg/dL, ranging from −0.057 to +0.009; group 2, mean 
of −0.0098 mg/dL, ranging from −0.048 to +0.028; 
P = 0.71). The variations in creatinine clearance levels 
(pre-PCI vs. post-PCI) were also negative, confirming the 
worsening of renal function after PCI (group 1, mean of 
−2.71 mL/min/1.73 m², ranging from −5.76 to +0.23; 
group 2, mean of −1.10 mL/min/1.73 m², ranging from 
−4.72 to +2.51; P = 0.54). The analysis of the percen-
tage change in creatinine clearance indicated that the 
values for group 1 and group 2 were both close to 
1, as the variation in pre- and post-procedure creati-
nine clearance values was very small (group 1, mean 
post-CrCl/pre-CrCl = 0.98, group 2, mean post-CrCl/
pre-CrCl = 1.00; P = 0.59). These data are shown in 
summarized form in Table 2.
The figure shows the presence of individual varia-
tion in serum creatinine and creatinine clearance before 
and after PCI in both groups.
The diabetics (31.1% of the study population) were 
equally distributed between the two groups (29.9% vs. 
32.4% for groups 1 and 2, respectively, P = 0.89). The 
overall incidence of CIN was 14.2% and did not differ 
Oliveira et al. 
Rosuvastatin in peri-PCI for Prevention of CIN
Rev Bras Cardiol Invasiva. 
2012;20(3):303-8
306
between the two groups (15% vs. 13.6% for groups 1 
and 2, respectively, P = 0.75). The evaluation of the 
variation in serum creatinine levels and creatinine 
clearence rates also indicated a slight worsening of renal 
function in the diabetic subgroup, with no statistical 
significance for either group (Table 3).
The patients with renal dysfunction (13.3% of the 
studied population) were equally distributed between 
the two groups (11.9% vs. 14.7% for groups 1 and 2, 
respectively; P = 0.82), and the incidence of CIN in 
these patients was 5.6%, with no difference between 
the two groups (12.5% vs. 0% for groups 1 and 2, 
respectively; P = 0.93). The serum creatinine and crea-
tinine clearance evaluation showed positive variances 
and a discreet improvement in renal function in both 
groups; however, these values were not statistically 
significant (Table 4).
discussion
The incidence of CIN in the population of patients 
on chronic statin use undergoing elective PCI was 8.1%. 
A maximal booster dose (40 mg) of a powerful next-
generation statin (rosuvastatin) provided two to six hours 
before the procedure failed to prevent the occurrence 
of CIN. This observation extends to the subgroups of 
patients with diabetes and renal dysfunction.
Several pathological mechanisms have been linked 
to CIN. The contrast medium stimulates the macula 
densa of the kidneys to produce adenosine, release 
angiotensin, vasopressin and endothelin, and decrease 
the synthesis of nitric oxide, causing hypoxia in the renal 
medulla. Later, other renal injury mechanisms, such as 
oxidative stress, the release of inflammatory cytokines, 
and complement activation promote the development 
of cellular lesions (cytoplasmic vacuolisation), necro-
sis, interstitial inflammation, and tubular obstruction. 
Statins may act during these stages to downregulate 
the angiotensin receptor, decrease endothelin synthe-
sis, increase nitric oxide bioavailability, decrease the 
expression of endothelial adhesion molecules, limit 
the production of oxygen reactive species, and protect 
against complement-mediated injury.8
A booster dose of rosuvastatin was administered two 
to six hours before the procedure to ensure that tissues 
were exposed to contrast medium during the peak serum 
concentration of rosuvastatin, which occurs approximately 
five hours after administration. Some anti-inflammatory 
effects were detected in the first 24 hours after the 
administration of a single 40 mg dose of pravastatin.10
This and other studies evaluating the role of statins 
in CIN prevention have yielded different and sometimes 
contradictory results. However, it is necessary to un-
derstand the different methodologies and the different 
study populations.
For instance, in the Atorvastatin for Reduction of 
Myocardial Damage during Angioplasty-Contrast-Indu ced 
Nephropathy (ARMyDA CIN) study, the administration of 
a high dose of atorvastatin (80 mg 40 hours before and 
12 mg two hours before the procedure) reduced the 
incidence of CIN in the treatment group compared to 
the placebo group (5% vs. 13.2%, P = 0.046).8
However, two important considerations must be 
made when comparing the results of the ARMyDACIN 
study with this analysis: 1) the patients included in the 
tAbLE 2 
Changes in serum creatinine levels (pre-Cr/post-Cr), creatinine clearance rates (post-CrCl/pre-CrCl),   
and creatinine clearance ratios (post-CrCl/pre-CrCl) in both groups
Group 1 (n = 67) Group 2 (n = 68) P
DCR, mg/dL −0.239 [−0.057 to +0.009] −0.0098 [−0.048 to +0.028] 0.71
DCrCl, mL/min/1.73 m2 −2.71 [-5.76 to +0.23] −1.10 [−4.72 to +2.51] 0.54
Post-PCI CrCl /pre-PCI CrCl 0.98 [0.94 to 1.01] 1.00 [0.96 to 1.05] 0.59
D = variation, CrCl = creatinine clearance, Cr = creatinine
Figure – Variation in serum creatinine levels and creatinine clearance rates 
for each patient included in the study. The graphs on the left illustrate the 
variation among the patients who received a booster dose of rosuvastatin, 
and the graphs on the right show data from the control group.
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ARMyDACIN study were not receiving any statins, 2) 
the study only included patients experiencing an acute 
coronary syndrome. In contrast, the population of the 
present study was already receiving chronic statin treat-
ment and was, therefore, experiencing the pleiotropic 
effects of this agent. Furthermore, the patients in the 
present series had stable or stabilized coronary disease, 
unlike ARMyDACIN, in which the patients with acute 
coronary disease, with an enhanced inflammatory pro-
file and associated endothelial dysfunction, may have 
reaped greater benefits from the anti-inflammatory and 
antioxidant effects of statins.
In 2011, Zhang et al.4 published a meta-analysis 
that included six registries and six randomized studies 
evaluating the chronic use of statins and the incidence 
of CIN. While four of the registries showed a nephro-
protective role of statins, the randomized studies showed 
no statistically significant association between the use of 
high doses of statins for a short period and the occur-
rence of CIN (relative risk [RR] 0.70, 95% confidence 
interval [95% CI]: 0.48 to 1.02), despite noticeable 
trend toward reduction in those receiving treatment.
Another meta-analysis published in 2011 investi-
gated eight randomized trials with patients who were 
or were not receiving chronic low-dose statin treatment, 
fin ding that pre-treatment with high doses of these drugs 
reduced the incidence of CIN in patients with normal 
pre-PCI renal function (RR 0.51; 95% CI: 0.34– 0.77; 
P = 0.001), but did not change the outcome for pa-
tients with previous renal dysfunction (RR 0.90; 95% 
CI: 0.49 –1.65; P = 0.73).11
Finally, the fact that a slight improvement was ob-
served in the renal function of patients with previous 
renal dysfunction (creatinine clearance < 60 mL/min), 
regardless of prior administration of rosuvastatin, deserves 
a brief comment. Although this study was not designed 
for this purpose, it is believed that this finding arose 
partly because this select group of patients received 
intravenous hydration before and after PCI, confirming 
the important role of hydration in the prevention of CIN.
study limitations
A potential limitation of this study is the short 
post-PCI time interval during which serum creatinine 
levels were measured. While the studies evaluating CIN 
have shown that the peak increase in creatinine occurs 
between 48 and 72 hours after exposure to contrast 
medium, the measurement in this study was obtained 
24 hours after PCI. However, this early assessment of 
renal function does not invalidate the study, as patients 
exhibiting serum creatinine increases of < 0.5 mg/dL 
in the first 24 hours after exposure to contrast medium 
have a low probability of developing CIN.12
Another possible limitation is the interval between 
the administration of rosuvastatin and the PCI procedure. 
tAbLE 3 
Variations in serum creatinine levels (pre-Cr/post-Cr), creatinine clearance rates (post-CrCl/pre-CrCl),  
and creatinine clearance ratios (post-CrCl/pre-CrCl) in diabetic patients
Group 1 Group 2 P
DCR, mg/dL −0.02 [−0.09 to +0.04] −0.05 [−0.12 to +0.02] 0.48
DCrCl, mL/min/1.73 m2 −2.39 [−9.03 to +4.25] −5.09 [−12.31 to +2.11] 0.53
Post-PCI CrCl /pre-PCI CrCl 0.98 [0.91 to 1.05] 0.97 [0.89 to 1.04] 0.61
D = variation, CrCl = creatinine clearance, Cr = creatinine
tAbLE 4 
Variations in serum creatinine levels (pre-Cr/post-Cr), creatinine clearance rates (post- CrCl/pre-CrCl),  
and creatinine clearance ratios (post-CrCl/pre-CrCl) in patients with previous kidney disease
Group 1 Group 2 P
DCR, mg/dL +0.02 [−0.14 to +0.19] +0.11 [−0.05 to +0.28] 0.63
DCrCl, mL/min/1.73 m2 +2.24 [−2.9 to +7.4] +9.8 [−1.6 to +21.3] 0.56
Post-PCI CrCl /pre-PCI CrCl 1.03 [0.91 to 1.14] 1.18 [0.97 to 1.39] 0.50
D = variation, CrCl = creatinine clearance, Cr = creatinine
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Although the pharmacokinetics of this drug indicate a 
peak serum concentration during the first hours after 
administration, it is possible that the pleiotropic effects 
of rosuvastatin may not occur until a later time point.
conclusions
The administration of a maximal (40 mg) booster 
dose of rosuvastatin to patients receiving chronic statin 
treatment has no renal protective effect during elective 
coronary angioplasty.
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